$4.07
0.12% yesterday
Nasdaq, Dec 26, 09:17 pm CET
ISIN
US92915B1061
Symbol
VYGR

Voyager Therapeutics, Inc. Stock price

$4.07
-0.03 0.73% 1M
+1.07 35.67% 6M
-1.60 28.22% YTD
-1.71 29.58% 1Y
-1.49 26.80% 3Y
-3.91 49.00% 5Y
-16.89 80.58% 10Y
-13.68 77.07% 20Y
Nasdaq, Closing price Wed, Dec 24 2025
+0.08 2.01%
ISIN
US92915B1061
Symbol
VYGR
Industry

Key metrics

Basic
Market capitalization
-
Enterprise Value
-
Net debt
positive
Cash
$208.9m
Shares outstanding
55.0m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
-
P/B
-
Financial Health
Equity Ratio
76.3%
Return on Equity
-21.7%
ROCE
-55.7%
ROIC
-215.0%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$31.3m | $36.2m
EBITDA
$-137.0m | $-127.7m
EBIT
$-141.0m | $-137.2m
Net Income
$-126.0m | $-117.3m
Free Cash Flow
$-118.3m
Growth (TTM | estimate)
Revenue
-80.9% | -54.7%
EBITDA
-919.3% | -69.2%
EBIT
-1,309.8% | -71.1%
Net Income
-586.9% | -80.4%
Free Cash Flow
-312.5%
Margin (TTM | estimate)
Gross
-
EBITDA
-437.4% | -352.3%
EBIT
-450.3%
Net
-402.4% | -323.6%
Free Cash Flow
-377.9%
More
EPS
$-2.1
FCF per Share
$-2.2
Short interest
7.3%
Employees
172
Rev per Employee
$470.0k
Show more

Is Voyager Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,079 stocks worldwide.

Voyager Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

18 Analysts have issued a Voyager Therapeutics, Inc. forecast:

17x Buy
94%
1x Hold
6%

Analyst Opinions

18 Analysts have issued a Voyager Therapeutics, Inc. forecast:

Buy
94%
Hold
6%

Financial data from Voyager Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
31 31
81% 81%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 37 37
1% 1%
117%
- Research and Development Expense 134 134
17% 17%
429%
-137 -137
919% 919%
-437%
- Depreciation and Amortization 4.02 4.02
21% 21%
13%
EBIT (Operating Income) EBIT -141 -141
1,310% 1,310%
-450%
Net Profit -126 -126
587% 587%
-402%

In millions USD.

Don't miss a Thing! We will send you all news about Voyager Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Voyager Therapeutics, Inc. Stock News

Neutral
GlobeNewsWire
about 2 months ago
CAMBRIDGE, United Kingdom and LEXINGTON, Mass., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Transition Bio, a drug discovery company focused on unlocking traditionally “undruggable” targets by leveraging biomolecular condensates, and Voyager Therapeutics (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, have entered into a drug discovery collaboratio...
Neutral
GlobeNewsWire
about 2 months ago
- Momentum building around tau: expect VY7523 clinical data and VY1706 clinical entry in 2026 -  - Sharpened focus on multi-modality pipeline with introduction of Voyager NeuroShuttle™ discovery program and small molecule collaboration - - Ended 3Q25 with cash position of $229 million, maintaining runway into 2028 - LEXINGTON, Mass., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. ...
Neutral
Seeking Alpha
4 months ago
Voyager Therapeutics, Inc. (NASDAQ:VYGR ) Citi's Biopharma Back to School Conference September 2, 2025 4:00 PM EDT Company Participants Alfred Sandrock - President, CEO & Director Todd Carter - Chief Scientific Officer Nathan Jorgensen - CFO, Principal Financial Officer & Principal Accounting Officer Conference Call Participants Samantha Semenkow - Citigroup Inc., Research Division Presentation...
More Voyager Therapeutics, Inc. News

Company Profile

Voyager Therapeutics, Inc. operates as a clinical-stage gene therapy company, which develops treatments for patients suffering from central nervous system. Its pipeline of gene therapy programs includes VY-AADC, VY-SOD101, VY-HTT01, VY-FXN01, Tau Program, and VY-NAV01. The company was founded by Guangping Gao, Mark A. Kay, Krystof Bankiewicz and Phillip Zamore in June 2013 and is headquartered in Cambridge, MA.

Head office United States
CEO Alfred Sandrock
Employees 172
Founded 2013
Website www.voyagertherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today